Trial Profile

University of Alabama at Birmingham (UAB) Adult CBD Program

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 30 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cannabidiol (Primary)
Indications Epilepsy
Focus Adverse reactions; Expanded access

Most Recent Events

01 Sep 2021 Results of an analysis assessing the longitudinal impact of highly purified cannabidiol on the electroencephalogram, a comparison between children and adults studies (NCT02700412 (adult arm) and NCT02695537 (pediatric arm)) published in the Epilepsy and Behavior
01 Apr 2021 Results (n=169) assessing two year efficacy and safety of cannabidiol for epilepsy from two studies: NCT02700412 (adult arm) and NCT02695537 (pediatric arm) published in the Epilepsy and Behavior
23 Apr 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com